Onco Wiki / Regime

Conversão de sirolímus (sarcoma Kaposi iatrogénico/transplante associado)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

Registro de base de conhecimento para auditoria. Conteúdo clínico provisório: não é uma prescrição. Um oncologista deve verificar fontes originais, aplicabilidade e estado de revisão. Regras completas e restrições estão no YAML.

Fonte YAML: registo completo

ComponentesDRUG-SIROLIMUS
IDREG-SIROLIMUS-KAPOSI-CONVERSION
TipoEsquema terapêutico
Estadoreviewed 2026-07-11 | pending_clinical_signoff
DoençasNenhuma declaração
FontesNenhuma declaração

Notas

New Regimen entity -- reuses the existing DRUG-SIROLIMUS Drug entity (already in the KB for the LAM indication) but is authored separately from REG-SIROLIMUS-LAM because the clinical context (transplant immunosuppression-conversion vs. LAM antiproliferative monotherapy), monitoring priorities (graft function vs. pulmonary function), and evidence base differ. Dosing is deliberately described qualitatively ("per transplant-team protocol") rather than with a single asserted mg/target-trough number: no KB-verifiable primary source for a Kaposi-conversion-specific sirolimus target trough was available at authoring time (CHARTER §8.3 -- do not invent a numeric threshold not already stated in a verified source). Conversion from calcineurin- inhibitor-based to mTOR-inhibitor-based immunosuppression for post-transplant Kaposi sarcoma is well described in the transplant literature (documented tumor regression in a meaningful fraction of patients) but must always be transplant-team-directed -- graft rejection is a real risk. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NIH-AIDS-2024 as the source for this regimen's dose-adjustment and between-visit-watchpoint items....

Usado por

Doença

Indicação